Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Hepatology International - Tập 14 Số 5 - Trang 690-700 - 2020
Shiv Kumar Sarin1, Ashok Choudhury1, George Lau2, Ming‐Hua Zheng3, Dong Ji4,2, Sherief Abd-Elsalam5, Jangsun Hwang6, Xiaolong Qi7, Ian Homer8, Jeong Ill Suh9, Jun-Gi Park9, Opass Putcharoen10, Apichat Kaewdech11, Teerha Piratvisuth11, Sombat Treeprasertsuk10, Soo‐Young Park12, Salisa Wejnaruemarn10, Diana A. Payawal13, Oidov Baatarkhuu14, Sang Hoon Ahn15, Chang Dong Yeo15, Uzziel Romar Alonzo13, Tserendorj Chinbayar16, Imelda Maria Loho17, Osamu Yokosuka18, Wasim Jafri19, Soek‐Siam Tan20, Lau Ing Soo20, Tawesak Tanwandee21, Rino Alvani Gani22, Lovkesh Anand23, Eslam Saber Esmail5, Mai Khalaf5, Shahinul Alam24, Chun‐Yu Lin25, Wan‐Long Chuang25, Arvinder S. Soin26, Hitendra Garg27, Kemal Fariz Kalista28, Badamnachin Batsukh14, Hery Purnomo29, Vijay Pal Dara30, Pravin Rathi31, Mamun Al Mahtab24, Akash Shukla32, Manoj Kumar Sharma1, Masao Omata33,34
1Department of Hepatology and Liver Transplant, Institute of Liver and Biliary Sciences, New Delhi, India
2Humanity and Health Clinical Trial Center, Hong Kong SAR, China
3Department of Hepatology, NAFLD Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4Fuyang Second People's Hospital, Fuyang, China
5Tropical Medicine and Infectious Diseases Department, Tanta University, Tanta, Egypt
6Keimyung University Dongsan Hospital, Daegu, South Korea
7CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China
8Institute of Digestive and Liver Diseases, St. Luke’s Medical Center, Global City, Philippines
9Department of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea
10Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross, Bangkok, Thailand
11Gastroenterology and Hepatology Unit, Department of Medicine, Prince of Songkla University, Songkhla, Thailand
12Kyungpook National University Hospital, Daegu, South Korea
13Department of Internal Medicine, Fatima University Medical Center, Valenzuela, Philippines
14Department of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
15Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
16National Center for Communicable Diseases, Ulan Bator, Mongolia
17Department of Gastroenterology and Hepatology “Dharmais”, National Cancer Hospital, Jakarta, Indonesia
18Chiba University, Chiba, Japan
19Department of Medicine, WGO Training Center, Aga Khan University, Karachi, Pakistan
20Department of Hepatology, Selayang Hospital, Batu Caves, Malaysia
21Division of Gastroenterology, Department of Medicine, Faculty of Siriraj Hospital, Mahidol University, Bangkok, Thailand
22Division of Hepatobiliary, Cipto Mangunkusuamo Hospital, University of Indonesia, Jakarta, Indonesia.
23Hepatologist, Manipal Hospital, New Delhi, India
24Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
25Division of Infectious Diseases, School of Medicine, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
26Liver Transplant Surgery, Medanta, The Medicity, Gurugram, India
27Hepatologist and Gastroenterologist, Indraprastha Apollo Hospital, New Delhi, India
28Faculty of Medicine, Cipto Mangunkusumo Hospitall, Universitas, Jakarta, Indonesia
29Kariadi Hospital, Diponegoro University, Semarang, Indonesia
30Yerevan Medical University, Yerevan, Armenia
31Department of Gastroenterology, T.N. Medical College, B.Y.L. Nair. Ch. Hospital, Mumbai, India
32Department of Gastroenterology, Seth GSMC and KEM Hospital, Mumbai, India
33Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu, Japan
34The University of Tokyo, Tokyo, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Coronavirus disease (COVID-19) Situation Report – 113. Data as received by WHO from national authorities. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200512-covid-19-sitrep-113.pdf?sfvrsn=feac3b6d_2.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565–574

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. https://doi.org/10.1016/s2213-2600(20)30079-5

Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi 2020;36:E005

Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020. https://doi.org/10.1002/jmv.25726 (epub ahead of print)

Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020. https://doi.org/10.1038/s41368-020-0074-x

Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020 (online ahead of print)

Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/S2468-1253(20)30057-1

Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver damage. medRxiv. https://doi.org/10.1101/2020.02.26.20026971

Li J, Jian-Gao F. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020. https://doi.org/10.14218/JCTH.2020.00019

Feng G, Zheng KI, Yan Q-Q, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8(1):18–24

Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020. https://doi.org/10.1038/s41379-020-0536-x

D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020 (online ahead of print)

Sarin SK. Fast, faster, and fastest: science on the run during COVID-19 drama—do not forget the liver. Hepatol Int. 2020. https://doi.org/10.1007/s12072-020-10042-0

Eslam M, Sanyal AJ, George J, on behalf of the International Consensus Panel, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312

Yang AP, Liu J, Tao W, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020. https://doi.org/10.1016/j.intimp.2020.106504

Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014;61(6):1385–1396. https://doi.org/10.1016/j.jhep.2014.08.010

Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep 2016;18(12):61 PMID: 27747458

Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. WHO Interim guidance. COVID-19: Laboratory and diagnosis. 2020. https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.

Clinical management of COVID-19. WHO interim guidance. COVID-19: Clinical care. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19.

Stefan N, Birkenfeld AL, Schulze MB, et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020. https://doi.org/10.1038/s41574-020-0364-6

Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020;14:535–545

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Implication of non- alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.03.044

Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan City, China. Liver Int. 2020 (online ahead of print)

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J Infect. 2020. https://doi.org/10.1016/j.jinf.2020.03.037

Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.04.006

Lei F, Liu YM, Zhou F, Qin JJ, Zhang P. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020. https://doi.org/10.1002/hep.31301

Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017;66:1154–1164

Sarin SK, Choudhury A, Sharma MK, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int 2019;13(4):353–390

Thông tin
Thông tin xuất bản

Hepatology International

Tập 14 Số 5

690-700

Thông tin tác giả